Drug intelligence / Profile preview

betaprodine

Development stage
Unknown
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous, Subcutaneous, Intramuscular
01

Overview

Betaprodine is a synthetic opioid analgesic chemically related to meperidine, notable for its rapid onset and short duration of action. It acts primarily as an agonist at mu-opioid receptors in the central nervous system, leading to inhibition of neurotransmitter release involved in pain transmission and resulting in analgesia. Betaprodine has been used experimentally for pain management in settings such as obstetrics, pre-operative medication, minor surgical procedures, and dental procedures. It is significantly more potent than morphine (up to 50 times stronger) but produces more euphoria and side effects compared to its stereoisomer alphaprodine. Betaprodine is classified as a Schedule I controlled substance under the DEA due to its high potential for abuse and lack of accepted medical use in the United States[1][2][3][4][5][6].

Other names
betaprodine hydrochloride
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on betaprodine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on betaprodine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call